SCHEMBL349358

SCHEMBL349358

CC(C)C(=O)O[C@H](OC(=O)Nc1ccc([C@H](C)CC(=O)O)cc1)C(C)C

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CASP3 P42574 5/20 0.42
ITGB1 P05556 3/20 0.42
ITGA4 P13612 3/20 0.42
FFAR1 O14842 3/20 0.42
NPC1 O15118 2/20 0.41
HPGD P15428 2/20 0.41
RAB9A P51151 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
CASP7 P55210 1/20 0.41
CASP9 P55211 1/20 0.41
CASP6 P55212 1/20 0.41
CASP8 Q14790 1/20 0.41
MAPT P10636 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
IDO1 P14902 1/20 0.39
TSHR P16473 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL351929 1.00 CASP3 (0.42) CASP3ITGB1ITGA4FFAR1NPC1
SCHEMBL351084 0.88 FFAR1 (0.43) CASP3ITGB1ITGA4FFAR1NPC1
SCHEMBL348939 0.88 FFAR1 (0.43) CASP3ITGB1ITGA4FFAR1NPC1
SCHEMBL349357 0.82 CRHBP (0.45) NPC1HPGDRAB9ASMN1; SMN2L3MBTL1
SCHEMBL351928 0.82 CRHBP (0.45) NPC1HPGDRAB9ASMN1; SMN2L3MBTL1
SCHEMBL363979 0.77 HPGD (0.41) CASP3NPC1HPGDRAB9ASMN1; SMN2
Arbaclofen Placarbil SCHEMBL2472988 0.72 GABBR2 (0.47) RAB9AL3MBTL1MAPTCYP1A2CYP2D6
Arbaclofen Placarbil SCHEMBL351833 0.72 GABBR2 (0.47) RAB9AL3MBTL1MAPTCYP1A2CYP2D6
SCHEMBL351696 0.72 FNTA (0.39) CASP3FFAR1HPGDMAPTFNTA
Arbaclofen Placarbil SCHEMBL3375708 0.72 GABBR2 (0.47) RAB9AL3MBTL1MAPTCYP1A2CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120016021-A1 METHODS OF TREATING FRAGILE X SYNDROME, DOWN'S SYNDROME, AUTISM AND RELATED DISORDERS XENOPORT, INC. (US) 2012-01-19 US claimed
US-20120016021-A1 METHODS OF TREATING FRAGILE X SYNDROME, DOWN'S SYNDROME, AUTISM AND RELATED DISORDERS XENOPORT, INC. (US) 2012-01-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120016021-A1 METHODS OF TREATING FRAGILE X SYNDROME, DOWN'S SYNDROME, AUTISM AND RELATED DISORDERS GABBR2, GABBR1, GABRB1 CASP3 2282/4885ITGB1 4034/4885ITGA4 4539/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.